Belmedpreparaty Company of Belarus and Cuba’s Center for Gene Engineering and Biotechnology signed an agreement on marketing and distribution of the original biotechnology medicine Heberprot-P to treat diabetic foot ulcer. The agreement envisages partial manufacturing of the medicine at Belmedpreparaty Company and its further supplies to the Healthcare Ministry. The agreement also stipulates the relevant training of Belarusian medical workers on the use of the medication.
Director General of the Cuba’s Center for Gene Engineering and Biotechnology Luis Herrera Martinez paid a visit to Belarus on 29-31 October. The Cuban official got familiar with the healthcare system of Belarus, visited Belmedpreparaty Company and a Minsk-based hospital.